142 related articles for article (PubMed ID: 29758480)
1. Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
Calhoun BC; Mosteller B; Warren D; Smith M; Jordi Rowe J; Lanigan CP; Mrazeck KC; Walker E; Newell AH; Jones R
Ann Diagn Pathol; 2018 Aug; 35():21-26. PubMed ID: 29758480
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
3. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
5. [Reliability of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression in breast cancer evaluated by immunohistochemistry].
Gu CS; Ying M; He YJ; Liu YQ; Dong B; Ouyang T; Lu AP
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(32):2571-3. PubMed ID: 24351599
[TBL] [Abstract][Full Text] [Related]
6. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
7. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
[TBL] [Abstract][Full Text] [Related]
8. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
Francis GD; Dimech M; Giles L; Hopkins A
J Clin Pathol; 2007 Nov; 60(11):1277-83. PubMed ID: 17259294
[TBL] [Abstract][Full Text] [Related]
9. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
[TBL] [Abstract][Full Text] [Related]
10. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
Sheikh UN; Cohen C; Siddiqui MT
Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
[TBL] [Abstract][Full Text] [Related]
11. [Comparative immunohistochemistry study of different antibodies clones for detection of breast cancer markers (estrogen receptor, progesterone receptor, HER2/neu, Ki-67)].
Kalinin DV; Samoylova DV; Danilova NV; Germanovich NY; Kuznetsova OA; Zavalishina LE
Arkh Patol; 2024; 86(2):14-20. PubMed ID: 38591902
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.
Mouttet D; Laé M; Caly M; Gentien D; Carpentier S; Peyro-Saint-Paul H; Vincent-Salomon A; Rouzier R; Sigal-Zafrani B; Sastre-Garau X; Reyal F
PLoS One; 2016; 11(2):e0146474. PubMed ID: 26829108
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
[TBL] [Abstract][Full Text] [Related]
14. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones.
Qiu J; Kulkarni S; Chandrasekhar R; Rees M; Hyde K; Wilding G; Tan D; Khoury T
Am J Clin Pathol; 2010 Nov; 134(5):813-9. PubMed ID: 20959666
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
16. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
17. Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
Jung M; Song SG; Cho SI; Shin S; Lee T; Jung W; Lee H; Park J; Song S; Park G; Song H; Park S; Lee J; Kang M; Park J; Pereira S; Yoo D; Chung K; Ali SM; Kim SW
Breast Cancer Res; 2024 Feb; 26(1):31. PubMed ID: 38395930
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
19. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
